Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism

Circulation

Volumn 100, Issue 10, 1999, Pages 1095-1101

  Figtree, Gemma A ^b   Lu, Ying Qing ^a   Webb, Carolyn M ^a   Collins, Peter ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b NONE

Author keywords

Arteries; Endothelium; Nitric oxide; Raloxifene

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL; ESTROGEN; ESTROGEN RECEPTOR; NITRIC OXIDE; RALOXIFENE;

ANIMAL TISSUE; ARTICLE; CALCIUM ANTAGONISM; CANCER RISK; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; FEMALE; HEART PROTECTION; HYPERPOLARIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TISSUE SPECIFICITY;

EID: 0033533491     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.10.1095     Document Type: Article

References (46)

1. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med. 1991;325:756-762.
2. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335: 453-461.
3. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol. 1991;104:1033-1037.
4. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol. 1995;26:807-814.
5. Chester AH, Jiang C, Borland JA, Yacoub MH, Collins P. Estrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron Artery Dis. 1995;6:417-422.
6. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
7. 2 in porcine coronary artery. Circulation. 1995;91:2619-2626.
8. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 1992;106:739-745.
9. Vedernikov YP, Liao QP, Jain V, Saade GR, Chwalisz K, Garfield RE. Effect of chronic treatment with 17beta-estradiol and progesterone on endothelium-dependent and endothelium-independent relaxation in isolated aortic rings from ovariectomized rats. Am J Obstet Gynecol. 1997;176:603-608.
10. Bell DR, Rensberger HJ, Koritnik DR, Koshy A. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries. Am J Physiol. 1995;268:H377-H383.
11. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation following acute estrogen withdrawal. Circulation. 1994;90:1964-1968.
12. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 1988; 244:19-22.
13. Williams SP, Shackelford DP, Iams SG, Mustafa SJ. Endothelium-dependent relaxation in estrogen-treated spontaneously hypertensive rats. Eur J Pharmacol. 1988;145:205-207.
14. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89: 11259-11263.
15. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill J, Poole-Wilson PA. Estradiol-17β attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 1995;92:24-30.
16. + channels. Circ Res. 1996;79:1024-1030.
17. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, Schnaper W. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation. 1996;94:1402-1407.
18. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
19. Harris RB, Laws A, Reddy VM, King A, Haskell WL. Are women using postmenopausal estrogens? A community survey. Am J Public Health. 1990;80:1266-1268.
20. Judd HL, Meldrum DR, Deftos LJ, Henderson BE. Estrogen replacement therapy: indications and complications. Ann Intern Med. 1983;98: 195-205.
21. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63-69.
22. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 1994;135:2001-2005.
23. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835-842.
24. Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL. Antiestrogenic properties of raloxifene. Pharmacology. 1995;50:209-217.
25. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci. 1995;761:355-360.
26. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL, Monroe A, Cullinan GJ, Glasebrook AL, Bryant HU. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther. 1997;280:146-153.
27. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A, Shah AS, Huster WJ, Draper MW, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
28. Bjarnason NH, Haarbo J, Byijalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Circulation. 1997;96:1964-1969.
29. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 1998;83:721-726.
30. Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibition of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol. 1989;96:418-424.
31. Quayle JM, Standen NB, Stanfield PR. The voltage-dependent block of ATP-sensitive potassium channels of frog skeletal muscle by caesium and barium ions. J Physiol. 1988;405:677-697.
32. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153:1251-1256.
33. Pohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res. 1989;65:1798-1803.
34. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867-3873.
35. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103:401-406.
36. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93:5925-5930.
37. Murad F. Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. Adv Pharmacol. 1994;26:19-33.
38. Murad F. The nitric oxide-cyclic GMP signal transduction system for intracellular and intercellular communication. Recent Prog Horm Res. 1994;49:239-248.
39. + channels are stimulated by cyclic guanosine monophosphate-dependent protein kinase in canine coronary artery smooth muscle cells. Pflugers Arch. 1993;423:167-172.
40. Wellman GC, Brayden JE, Nelson MT. A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Clin Exp Pharmacol Physiol. 1996;23:260-266.
41. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol. 1992;263:H271-H275.
42. Johnston SD, Haynes BP, Sacks NM, McKinna JA, Griggs LJ, Jarman M, Baum M, Smith IE, Dowsett M. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res Treat. 1993;28:241-250.
43. Johnston SD, Haynes BP, Smith IE, Jarman M, Sacks NM, Ebbs SR, Dowsett M. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet. 1993;342: 1521-1522.
44. Mugge A, Riedel M, Barton M, Kuhn M, Lichtlen PR. Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc Res. 1993;27:1939-1942.
45. Webb CM, Rosano GMC, Collins P. Oestrogen improves exercise-induced myocardial ischaemia in women. Lancet. 1998;351: 1556-1557.
46. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, Creager MA. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998;98:1158-1163.